Abstract
Findings of a retrospective data analysis on outcome of temozolomide singe agent and temozolomide/capecitabine in patients with gastroenteropancreatic neuroendocrine neoplasms (gep-nen) in the european neuroendocrine tumour centre of excellence at the beatson west of scotland cancer centre, glasgow
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have